Department of Pediatric Hematology/Oncology, University at Buffalo, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Department of Paediatric and Adolescent Oncology, Gustave Roussy, Villejuif, France.
Br J Haematol. 2019 Jun;185(6):1111-1124. doi: 10.1111/bjh.15783. Epub 2019 Jan 30.
Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of malignancies. Most NHLs in children, adolescent and young adult patients are aggressive lymphomas that are generally treated with multi-agent chemotherapy or immunochemotherapy regimens. While overall survival is high, the treatment can lead to a high rate of acute and long-term toxicity. However, in the rarer instance of relapsed or refractory disease, outcomes are dismal. Novel therapeutic approaches to the treatment of both T-cell and B-cell NHLs are critical to improve outcomes while also minimising the associated toxicity of current treatment regimes. Potential therapeutic approaches in development include humoral and cellular immunotherapies, small molecule inhibitors of relevant signalling pathways and epigenetic modifying agents. In this review, we will highlight the current state of development of agents of interest with a focus on agents relevant to childhood, adolescent and young adult NHL.
非霍奇金淋巴瘤（NHL）是一组异质性的恶性肿瘤。大多数儿童、青少年和年轻成年患者的 NHL 是侵袭性淋巴瘤，通常采用多药物化疗或免疫化疗方案进行治疗。尽管总体生存率较高，但治疗可能会导致急性和长期毒性的高发生率。然而，在罕见的复发或难治性疾病情况下，结局较差。开发针对 T 细胞和 B 细胞 NHL 的新型治疗方法对于改善结局，同时最小化当前治疗方案相关的毒性至关重要。正在开发中的潜在治疗方法包括体液和细胞免疫疗法、相关信号通路的小分子抑制剂和表观遗传修饰剂。在这篇综述中，我们将重点介绍与儿童、青少年和年轻成年 NHL 相关的有前途的药物的最新开发情况。
